Trends in coagulation factor replacement therapy and medical costs in patients with haemophilia in Taiwan: A population-based, 15-year analysis.
Miyuki Hsing-Chun HsiehShyh-Shin ChiouTzu-Chi LiaoYea-Huei Kao YangEdward Chia-Cheng LaiPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)
Reimbursement for prophylactic CFRT facilitated growth in rates of prophylactic CFRT and increased related costs, but curbed rising non-CFRT costs. These findings provide strong grounds for future cost-effectiveness studies to leverage prophylactic CFRT for its therapeutic benefits.